Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Johnson and Johnson
Express Scripts
Medtronic
Moodys

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR DROXIA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Droxia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00354913 ↗ Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed National Cancer Institute (NCI) Phase 2 2005-05-01 RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.
NCT00354913 ↗ Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed Novartis Pharmaceuticals Phase 2 2005-05-01 RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.
NCT00354913 ↗ Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed Duke University Phase 2 2005-05-01 RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.
NCT01389024 ↗ Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease Active, not recruiting Children's Hospital of Philadelphia Phase 2 2011-10-01 This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo for 36 months. Neither the study doctors nor the participants will know which treatment they are receiving.
NCT01389024 ↗ Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease Active, not recruiting Children's Mercy Hospital Kansas City Phase 2 2011-10-01 This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo for 36 months. Neither the study doctors nor the participants will know which treatment they are receiving.
NCT01389024 ↗ Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease Active, not recruiting Columbia University Phase 2 2011-10-01 This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo for 36 months. Neither the study doctors nor the participants will know which treatment they are receiving.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Droxia

Condition Name

Condition Name for Droxia
Intervention Trials
Sickle Cell Disease 5
Sickle Cell Anemia 3
Head and Neck Squamous Cell Carcinoma 2
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Droxia
Intervention Trials
Anemia, Sickle Cell 7
Anemia 3
Carcinoma 2
Squamous Cell Carcinoma of Head and Neck 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Droxia

Trials by Country

Trials by Country for Droxia
Location Trials
United States 32
Congo, The Democratic Republic of the 1
Brazil 1
Congo 1
Uganda 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Droxia
Location Trials
Tennessee 3
North Carolina 3
Missouri 3
Texas 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Droxia

Clinical Trial Phase

Clinical Trial Phase for Droxia
Clinical Trial Phase Trials
Phase 3 2
Phase 2 7
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Droxia
Clinical Trial Phase Trials
Active, not recruiting 3
Terminated 3
Recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Droxia

Sponsor Name

Sponsor Name for Droxia
Sponsor Trials
National Cancer Institute (NCI) 4
National Heart, Lung, and Blood Institute (NHLBI) 3
St. Jude Children's Research Hospital 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Droxia
Sponsor Trials
Other 59
NIH 10
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.